ZA976368B - High-affinity interleukin-4 muteins. - Google Patents

High-affinity interleukin-4 muteins.

Info

Publication number
ZA976368B
ZA976368B ZA9706368A ZA976368A ZA976368B ZA 976368 B ZA976368 B ZA 976368B ZA 9706368 A ZA9706368 A ZA 9706368A ZA 976368 A ZA976368 A ZA 976368A ZA 976368 B ZA976368 B ZA 976368B
Authority
ZA
South Africa
Prior art keywords
muteins
affinity interleukin
interleukin
affinity
Prior art date
Application number
ZA9706368A
Other languages
English (en)
Inventor
Jeffrey Greve
Armen B Shanafelt
Steven Roczniak
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of ZA976368B publication Critical patent/ZA976368B/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA9706368A 1996-07-19 1997-07-18 High-affinity interleukin-4 muteins. ZA976368B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68780396A 1996-07-19 1996-07-19

Publications (1)

Publication Number Publication Date
ZA976368B true ZA976368B (en) 1998-02-19

Family

ID=24761912

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9706368A ZA976368B (en) 1996-07-19 1997-07-18 High-affinity interleukin-4 muteins.

Country Status (24)

Country Link
EP (1) EP0939817B1 (zh)
JP (1) JP2000515016A (zh)
KR (1) KR100468553B1 (zh)
CN (1) CN1201006C (zh)
AR (2) AR007917A1 (zh)
AT (1) ATE310821T1 (zh)
AU (1) AU718794B2 (zh)
BR (1) BR9710733B1 (zh)
CA (1) CA2259940C (zh)
DE (1) DE69734723T2 (zh)
DK (1) DK0939817T3 (zh)
ES (1) ES2252786T3 (zh)
HK (1) HK1022717A1 (zh)
HU (1) HU224973B1 (zh)
ID (1) ID17491A (zh)
IL (2) IL127934A0 (zh)
MY (1) MY124565A (zh)
NZ (2) NZ505238A (zh)
PL (1) PL188738B1 (zh)
RU (1) RU2202364C2 (zh)
TR (1) TR199900100T2 (zh)
TW (1) TW496871B (zh)
WO (1) WO1998003654A2 (zh)
ZA (1) ZA976368B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0911401A1 (en) * 1997-10-21 1999-04-28 Bayer Ag Muteins of interleukin 4 showing low-affinity and short-term interaction with the common gamma chain
EP1022337B1 (en) * 1999-01-20 2006-07-26 Bayer HealthCare AG Plasmids, their construction and their use in the manufacture of interleukin-4 and interleukin-4 muteins
DE69929638T2 (de) 1999-01-20 2006-09-21 Bayer Healthcare Ag Plasmide, deren Konstruktion und Anwendung zur Herstellung von Interleukin-4 und dessen Muteine
CN1306030C (zh) * 2001-09-28 2007-03-21 中山大学 一种人白细胞介素－10基因序列及含该基因序列的大肠杆菌
WO2004064860A1 (en) * 2003-01-17 2004-08-05 Children's Hospital Medical Center Use of tff2, or agents inducing tff2, in the therapy of allergies
US7404957B2 (en) 2003-08-29 2008-07-29 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
US7785580B2 (en) 2003-08-29 2010-08-31 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
JP2009525267A (ja) * 2006-01-11 2009-07-09 アエロヴァンス インコーポレイティッド ヒトおよび非ヒト霊長類において喘息を処置するための方法および組成物
WO2017001568A1 (en) 2015-07-01 2017-01-05 Universitat De Lleida Treatment and prevention of amyotrophic lateral sclerosis
CN113227369A (zh) * 2018-12-19 2021-08-06 生物制药翻译学院德绍研究有限公司 具有改善的酶学特性的胰蛋白酶变体
CN113527485A (zh) * 2020-04-17 2021-10-22 上海麦济生物技术有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN112442504B (zh) * 2020-12-10 2023-01-24 电子科技大学 一种重组草鱼白介素-12活性蛋白的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004667A1 (en) * 1986-12-19 1988-06-30 Immunex Corporation Human interleukin-4 muteins
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
AU4289193A (en) * 1992-04-17 1993-11-18 University Hospital, The Mutant cytokines having increased receptor affinity
CA2256459A1 (en) * 1996-06-14 1997-12-18 Bayer Corporation T-cell selective interleukin-4 agonists

Also Published As

Publication number Publication date
EP0939817A2 (en) 1999-09-08
TR199900100T2 (xx) 1999-04-21
NZ505238A (en) 2001-06-29
ID17491A (id) 1998-01-08
EP0939817B1 (en) 2005-11-23
KR20000067914A (ko) 2000-11-25
DK0939817T3 (da) 2006-01-23
CN1201006C (zh) 2005-05-11
BR9710733A (pt) 1999-08-17
CA2259940C (en) 2008-09-23
KR100468553B1 (ko) 2005-01-29
IL182509A0 (en) 2007-09-20
ES2252786T3 (es) 2006-05-16
DE69734723T2 (de) 2006-06-22
TW496871B (en) 2002-08-01
HK1022717A1 (en) 2000-08-18
AR007917A1 (es) 1999-11-24
AU3654597A (en) 1998-02-10
BR9710733B1 (pt) 2012-02-22
HUP0000248A3 (en) 2003-09-29
ATE310821T1 (de) 2005-12-15
AR060630A2 (es) 2008-07-02
CA2259940A1 (en) 1998-01-29
IL127934A0 (en) 1999-11-30
HUP0000248A2 (hu) 2000-06-28
RU2202364C2 (ru) 2003-04-20
MY124565A (en) 2006-06-30
HU224973B1 (en) 2006-04-28
WO1998003654A3 (en) 1998-05-14
DE69734723D1 (de) 2005-12-29
WO1998003654A2 (en) 1998-01-29
PL188738B1 (pl) 2005-04-29
IL182509A (en) 2011-03-31
AU718794B2 (en) 2000-04-20
CN1230223A (zh) 1999-09-29
PL331253A1 (en) 1999-07-05
JP2000515016A (ja) 2000-11-14
NZ333748A (en) 2000-08-25

Similar Documents

Publication Publication Date Title
GB2319523B (en) Hydroxyphenyltriazines
GB2317174B (en) Hydroxyphenyltriazines
ZA972685B (en) Medicaments.
DE69723848D1 (en) 3-descladinose-2,3-anhydroerythromycin-derivate
ZA976368B (en) High-affinity interleukin-4 muteins.
GB9618974D0 (en) Medicaments
GB9611947D0 (en) Medicaments
GB9605293D0 (en) Medicaments
IL125919A0 (en) Cytokine designated lerk-8
GB9611167D0 (en) Medicaments
GB9619677D0 (en) Table
GB9613096D0 (en) Medicaments
ZA97533B (en) Table tennis table.
ZA971302B (en) Novel cytokine.
CA79135S (en) Table
CA79134S (en) Table
GB9611319D0 (en) Novel cytokine
PL104431U1 (en) Table
AU128694S (en) Table
PL104271U1 (en) Small at-the-bed table
GB9605859D0 (en) Medicaments
GB9605329D0 (en) Medicaments
GB9618975D0 (en) Medicaments
GB9623160D0 (en) Medicaments
GB9605328D0 (en) Medicaments